IGM Biosciences PAO Sells $583 in Stock for Tax Obligations

IGM Biosciences (IGMS) Principal Accounting Officer Steven Weber reported a sale of 486 shares of common stock on June 16, 2025.

Rhea-AI Filing Summary

IGM Biosciences (IGMS) Principal Accounting Officer Steven Weber reported a sale of 486 shares of common stock on June 16, 2025. The transaction was executed at a weighted average price of $1.1992 per share, with individual trades ranging from $1.17 to $1.22.

Key details of the transaction:

• The sale was specifically conducted to cover tax withholding obligations related to the vesting of restricted stock units
• Following the transaction, Weber maintains direct beneficial ownership of 26,530 shares
• The Form 4 was filed on June 28, 2025, with signature by power of attorney through Misbah Tahir

This transaction represents a routine share sale for tax purposes rather than a discretionary trading decision by the insider. The relatively small transaction size and its purpose suggest minimal significance for investor sentiment.

Insider Trade Summary

Net Seller: 486 shares

Net Sell 1 txn

Insider Weber Steven

Role PRINCIPAL ACCOUNTING OFFICER

Sold 486 shs ($582.81)

Type	Security	Shares	Price	Value
Sale	Common Stock	486	$1.1992	$582.81

Holdings After Transaction: Common Stock — 26,530 shares (Direct)

Footnotes (2)

1. F1. These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
2. F2. This transaction was executed in multiple trades at prices ranging from $1.17 to $1.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate sale price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares of IGMS stock did Principal Accounting Officer Steven Weber sell on June 16, 2025?

Steven Weber sold 486 shares of IGM Biosciences (IGMS) common stock on June 16, 2025. The sale was made to cover tax withholding obligations related to the vesting of restricted stock units.

What was the sale price of IGMS shares in Steven Weber's June 16, 2025 transaction?

The shares were sold at a weighted average price of $1.1992 per share. The transactions were executed in multiple trades with prices ranging from $1.17 to $1.22 per share.

How many IGMS shares does Steven Weber own after the June 16, 2025 transaction?

Following the reported transaction, Steven Weber directly owns 26,530 shares of IGM Biosciences (IGMS) common stock.

What is Steven Weber's role at IGMS and what type of transaction did he execute?

Steven Weber serves as the Principal Accounting Officer at IGM Biosciences. He executed a sale (S) transaction to cover tax withholding obligations related to the vesting of restricted stock units.

When was this Form 4 filed for IGMS relative to the transaction date?

The Form 4 was signed on June 20, 2025 (by Misbah Tahir with power of attorney) and filed on June 28, 2025, following the transaction date of June 16, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/20/2025 - 08:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weber Steven

(Last) (First) (Middle)

C/O IGM BIOSCIENCES, INC.

325 E. MIDDLEFIELD ROAD

(Street)

MOUNTAIN VIEW CA 94043

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IGM Biosciences, Inc. [ IGMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRINCIPAL ACCOUNTING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/16/2025		S(1)		486	D	$1.1992(2)	26,530	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

2. This transaction was executed in multiple trades at prices ranging from $1.17 to $1.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate sale price.

	/s/ Misbah Tahir, by power of attorney	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.